# Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma

> **NCT03502148** · PHASE1,PHASE2 · COMPLETED · sponsor: **Privo Technologies** · enrollment: 10 (actual)

## Conditions studied

- Oral Squamous Cell Carcinoma

## Interventions

- **DRUG:** PRV111 (Cisplatin Transmucosal System)

## Key facts

- **NCT ID:** NCT03502148
- **Lead sponsor:** Privo Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-19
- **Primary completion:** 2019-10-27
- **Final completion:** 2020-05-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03502148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03502148, "Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03502148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*